NIH Funds Influenza Research and Surveillance Network
Influenza scientists at five sites in the US are to receive funding from the National Institute of Allergy and Infectious Diseases (NIAID) to collaborate with investigators around the globe in a network designed to advance understanding of influenza viruses and how they cause disease.
In addition to basic research, investigators in the Centers of Excellence for Influenza Research and Surveillance (CEIRS) network also conduct domestic and international influenza surveillance studies with an emphasis on rapid characterization of viruses that have the potential to cause pandemics. The first CEIRS network was launched in 2007 by NIAID, part of the National Institutes of Health. NIAID today announced awards of the new contracts to continue the programme for 7 years.
“The CEIRS network exemplifies NIAID’s dual mission of conducting basic and applied influenza research, while maintaining the ability to respond rapidly in the event of an emerging public health threat,” said NIAID Director Anthony S. Fauci, MD. “CEIRS investigators have contributed greatly to our understanding of how influenza viruses emerge from wild and domestic animals, their adaptation to and global circulation throughout the human population and the interplay between the viruses and human immune responses.” Dr Fauci added that the CEIRS network also played a critical role in the nation’s response to the 2009 H1N1 influenza pandemic by, for example, quickly characterizing the virus and performing pre-clinical testing of candidate vaccines.
The geographic range of sample collection sites will be more tightly focused than previously on those regions where new influenza viruses are likely to emerge and the network will further integrate basic research with surveillance data gathering, said CEIRS project officer Diane Post, PhD, of NIAID’s Division of Microbiology and Infectious Diseases.
“A key mission of the CEIRS network is to foster innovative and collaborative basic research on influenza viruses, including how they evolve and adapt to animal and human hosts. The information we gain could help us understand why influenza pandemics occur and could assist health officials in taking steps to mitigate outbreaks,” Dr Post said.
Four of the new CEIRS contracts are to institutions that had received a 2007 award. One institution, Johns Hopkins University, will establish a new center. All will conduct surveillance and basic research projects. The network has a global reach, with collaborations established or planned at more than two dozen sites in Asia, Southeast Asia, the Middle East, South America, Europe and Australia. Funding for the first year of the contracts will total approximately $23 million.
“Proposed work from all five centers involves new and exciting research programs that hold the promise to answer fundamental questions pertaining to influenza in animals and people,” said Dr Post.
Related News
-
News A Day in the Life of a Start-Up Founder and CEO
At CPHI we work to support Start-Up companies in the pharmaceutical industry and recognise the expertise and innovative angles they bring to the field. Through our Start-Up Programme we have gotten to know some of these leaders, and in this Day in the ... -
News Biopharmaceutical manufacturing boost part of new UK government budget
In their national budget announced by the UK Labour Party, biopharmaceutical production and manufacturing are set to receive a significant boost in capital grants through the Life Sciences Innovative Manufacturing Fund (LSIMF). -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance